BR112014001287A2 - vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina - Google Patents

vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina

Info

Publication number
BR112014001287A2
BR112014001287A2 BR112014001287A BR112014001287A BR112014001287A2 BR 112014001287 A2 BR112014001287 A2 BR 112014001287A2 BR 112014001287 A BR112014001287 A BR 112014001287A BR 112014001287 A BR112014001287 A BR 112014001287A BR 112014001287 A2 BR112014001287 A2 BR 112014001287A2
Authority
BR
Brazil
Prior art keywords
leukemia virus
feline leukemia
vaccine containing
envelope gene
felv
Prior art date
Application number
BR112014001287A
Other languages
English (en)
Other versions
BR112014001287B1 (pt
Inventor
Poulet Hervé
Heidmann Thierry
Original Assignee
Centre Nat Rech Scient
Roussy Inst Gustave
Merial Ltd
Université Paris-Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Roussy Inst Gustave, Merial Ltd, Université Paris-Sud filed Critical Centre Nat Rech Scient
Publication of BR112014001287A2 publication Critical patent/BR112014001287A2/pt
Publication of BR112014001287B1 publication Critical patent/BR112014001287B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Abstract

resumo da patente de invenção para: “vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina”. a presente invenção fornece vetores que contêm e expressam, in vivo ou in vitro, antígenos de felv que induzem uma resposta imunológica em um animal ou ser humano contra felv, composições que compreendem os referidos vetores e/ou polipeptídeos de felv, métodos de vacinação contra felv e kits para utilização com os referidos métodos e composições.
BR112014001287-3A 2011-07-20 2012-02-02 vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina BR112014001287B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509912P 2011-07-20 2011-07-20
US61/509,912 2011-07-20
PCT/US2012/023658 WO2013012446A1 (en) 2011-07-20 2012-02-02 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

Publications (2)

Publication Number Publication Date
BR112014001287A2 true BR112014001287A2 (pt) 2017-02-21
BR112014001287B1 BR112014001287B1 (pt) 2020-12-08

Family

ID=45722710

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001287-3A BR112014001287B1 (pt) 2011-07-20 2012-02-02 vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina

Country Status (24)

Country Link
US (2) US8895027B2 (pt)
EP (1) EP2734230B1 (pt)
JP (2) JP6084970B2 (pt)
CN (1) CN103957932B (pt)
AU (2) AU2012284558B2 (pt)
BR (1) BR112014001287B1 (pt)
CA (1) CA2842055C (pt)
CY (1) CY1125328T1 (pt)
DK (1) DK2734230T3 (pt)
ES (1) ES2720150T3 (pt)
HR (1) HRP20190271T1 (pt)
HU (1) HUE043547T2 (pt)
IL (1) IL230460B (pt)
IN (1) IN2014CN00547A (pt)
LT (1) LT2734230T (pt)
MX (1) MX351642B (pt)
PL (1) PL2734230T3 (pt)
PT (1) PT2734230T (pt)
RS (1) RS58289B1 (pt)
RU (1) RU2591817C2 (pt)
SI (1) SI2734230T1 (pt)
TR (1) TR201901466T4 (pt)
WO (1) WO2013012446A1 (pt)
ZA (1) ZA201400349B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731659A (en) 2014-11-03 2018-10-26 Merial Inc Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2019068905A2 (en) * 2017-10-06 2019-04-11 Virbac FELINE VACCINES CONFERRING EARLY PROTECTION
CN111848785B (zh) * 2020-07-10 2022-09-06 青岛博隆基因工程有限公司 猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
DE3730599A1 (de) 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
EP0699758B1 (en) * 1988-12-13 2002-07-24 President And Fellows Of Harvard College Prototype felv isolates for use in disease models and vaccines
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
WO1996034109A1 (en) 1995-04-25 1996-10-31 Vical Incorporated Single-vial formulations of dna/lipid complexes
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
TR200503031T2 (tr) 1999-09-25 2005-09-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
AU2002365202A1 (en) 2001-11-09 2003-09-02 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
WO2004028562A2 (de) * 2002-09-23 2004-04-08 Mologen Ag Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
ZA200608178B (en) * 2004-03-30 2008-10-29 Roussy Inst Gustave Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
CA2570156C (en) 2004-06-04 2014-09-30 Merial Limited Needle-free administration of felv vaccines
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
DK1954308T3 (da) * 2005-09-16 2011-10-24 Merial Ltd Stabiliseringsmidler til frysetørrede vacciner
WO2008150404A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens

Also Published As

Publication number Publication date
JP2017052774A (ja) 2017-03-16
HUE043547T2 (hu) 2019-08-28
CY1125328T1 (el) 2023-03-24
IN2014CN00547A (pt) 2015-04-03
IL230460B (en) 2018-11-29
MX351642B (es) 2017-10-23
HRP20190271T1 (hr) 2019-03-22
CN103957932A (zh) 2014-07-30
ZA201400349B (en) 2015-08-26
RS58289B1 (sr) 2019-03-29
US8895027B2 (en) 2014-11-25
EP2734230B1 (en) 2018-11-21
AU2012284558A1 (en) 2014-02-20
DK2734230T3 (en) 2019-01-28
AU2012284558B2 (en) 2017-06-29
AU2017204298A1 (en) 2017-07-13
TR201901466T4 (tr) 2019-02-21
SI2734230T1 (sl) 2019-04-30
US9856295B2 (en) 2018-01-02
US20130022632A1 (en) 2013-01-24
CA2842055C (en) 2019-04-02
CN103957932B (zh) 2017-06-23
MX2014000625A (es) 2015-06-02
RU2591817C2 (ru) 2016-07-20
WO2013012446A1 (en) 2013-01-24
JP6240294B2 (ja) 2017-11-29
CA2842055A1 (en) 2013-01-24
NZ620566A (en) 2016-02-26
LT2734230T (lt) 2019-03-25
US20150030623A1 (en) 2015-01-29
PT2734230T (pt) 2019-02-27
IL230460A0 (en) 2014-03-31
ES2720150T3 (es) 2019-07-18
BR112014001287B1 (pt) 2020-12-08
PL2734230T3 (pl) 2019-07-31
EP2734230A1 (en) 2014-05-28
RU2014106295A (ru) 2015-08-27
JP6084970B2 (ja) 2017-02-22
JP2014528699A (ja) 2014-10-30

Similar Documents

Publication Publication Date Title
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MY184576A (en) Recombinant proteins and their therapeutic uses
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
BR112016013804A2 (pt) imunoterapia de câncer distribuindo antígenos mhc de classe ii usando um replicon de vlp
ES2721159T3 (es) Antígenos asociados a tumor independientes de MHC novedosos
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
MX348137B (es) Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
MX2019007924A (es) Vacunas contra la influenza.
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
BR112015012515A2 (pt) métodos para a indução de anticorpos
MX2013013812A (es) Vacunas geneticas contra el virus hendra y el virus nipah.
EA202091863A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
TN2010000500A1 (en) Leishmania vaccine using sand fly salivary immunogen
TR201907091T4 (tr) Yeni adjuvan kompozisyonları.
PL402193A1 (pl) Doustna kompozycja immunogenna przeciwko zakażeniom Clostridium difficile, zastosowanie przetrwalników Bacillus subtilis jako nośników dla antygenów oraz wyodrębnione rekombinowane geny kodujące białka płaszcza i antygeny FliD oraz FbpA

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: MERIAL LIMITED (US) , CENTRE NATIONAL DE LA RECHER

B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; INSTITUT GUSTAVE ROUSSY (FR) ; UNIVERSITE PARIS-SUD (FR) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)